Search Results 181-190 of 21214 for Inhibition

  1. A Study of Vulvovaginal Symptoms in Premenopausal Stage 0-III Breast Cancer Patients Treated on Aromatase Inhibitors and Ovarian Suppression - Mayo Clinic

    A Study of Vulvovaginal Symptoms in Premenopausal Stage 0-III Breast Cancer Patients Treated on Aromatase Inhibitors and Ovarian Suppression · Overview.

  2. Function and Dysfunction in Leukocytes - Mayo Clinic

    Determine how inhibition/activation of immune cell signaling of affects inflammation. Participation eligibility. Participant eligibility includes age, gender ...

  3. Cytotoxic Action of Novel Anti-Neoplastic Agents - Anticancer Drug Action Laboratory - Mayo Clinic Research

    These studies have led to early-phase clinical trials of cytarabine plus Chk1 inhibitors in acute myelogenous leukemia and gemcitabine or carboplatin plus ATR ...

  4. Central-acting agents - Mayo Clinic

    Central adrenergic inhibitors. Central alpha agonists. Central agonists. ; Clonidine (Duraclon, Nexiclon XR). Guanfacine (Intuniv). Methyldopa. ; Attention- ...

  5. Precision medicine for breast cancer - Mayo Clinic

    Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor ...

  6. Omeprazole (oral route) - Side effects & dosage - Mayo Clinic

    Omeprazole is a proton pump inhibitor (PPI). It works by decreasing the amount of acid produced by the stomach. This medicine is available both over-the ...

  7. A Study to Develop a Biobank of Samples from Patients Undergoing Therapy with PCSK9 Inhibitors - Mayo Clinic

    Develop a biobank of samples from patients undergoing therapy with PCSK9 inhibitors (FDA- approved in 2015, therapeutics for hypercholesterolemia) with the ...

  8. Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial - Mayo Clinic

    Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial · Overview · Participation ...

  9. Biological therapy for cancer - Mayo Clinic

    Immune checkpoint inhibitors and modulators. Immunoconjugates. Immunotherapy. Monoclonal antibodies. Targeted therapy. Tumor-infiltrating lymphocyte therapy.

  10. Viji Shridhar, Ph.D. - Mayo Clinic Faculty Profiles

    Shridhar observed an enhanced DNA damage response and increased sensitivity to the PARP inhibitor olaparib specifically and not other PARP inhibitors.